Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. (Abbreviated as: Tri-Prime Gene, Stock Code: 837344) has a registered capital of RMB 121.81 million. The company is a leader in China's gene engineering drug sector, specializing in the research, development, production, and commercialization of modern biopharmaceuticals, with core strengths in both fundamental research and clinical application development of gene engineering drugs.

Founded in 1992, Tri-Prime Gene was China's first enterprise named for proprietary gene engineering technologies. The company was co-founded by its inaugural Chairman, Professor Hou Yunde, and inaugural General Manager, Mr. Cheng Yongqing.

The company's flagship product, Recombinant Human Interferon α1b, was China's first Class I genetically engineered new drug with independent intellectual property rights, used for treating various viral diseases and malignant tumors. Its product Yundesu® (Human Interferon α1b) has established itself as a premium brand in China's gene engineering drug market, delivering significant economic and social benefits.

With strong R&D capabilities, Tri-Prime Gene's research center was approved in 2001 by China's Ministry of Personnel to establish a post-doctoral research workstation. The company holds numerous clinical-stage new drug projects at internationally advanced levels and possesses over 50 patents in China, the U.S. and other countries. Tri-Prime Gene has undertaken more than 20 national and Beijing municipal key scientific projects, and has obtained over 10 new drug certificates and production licenses.